DEFA14A: NovaBay Details Special Dividend, Annual Meeting

NovaBay Pharmaceuticals provided important details regarding its $0.80 per share special cash dividend and announced the record and meeting dates for its 2025 Annual Meeting of Stockholders.

Summary

• NovaBay Pharmaceuticals announced details for its one-time special cash dividend of $0.80 per share.
• The dividend is payable on September 29, 2025, to stockholders of record as of September 15, 2025.
• Due to the dividend representing over 25% of the common stock price, NYSE American will implement "due bill" trading procedures from September 15, 2025, through September 29, 2025.
• Stockholders selling shares during this "Dividend Right Period" will also be selling their right to the special dividend.
• The ex-dividend date is September 30, 2025.
• The 2025 Annual Meeting of Stockholders is scheduled for October 16, 2025, with a record date of September 22, 2025.
• A preliminary proxy statement for the Annual Meeting was filed on September 10, 2025, with a definitive proxy statement expected by the end of September 2025.

Sentiment

Score: 7

Explanation: The special dividend is a positive return to shareholders. Management's optimistic outlook and pursuit of strategic alternatives suggest potential future value creation, though the 'due bill' process adds a minor complexity for some traders. The 'Investment Transaction' could be a significant positive if it's a favorable deal.

Positives

• A one-time special cash dividend of $0.80 per share is being paid to stockholders of record.
• Management assures that the dividend payout will not hinder the pursuit of strategic transactions.
• The company is exploring several high-value strategic alternatives, indicating potential future growth or value creation.

Negatives

• Stockholders selling shares during the Dividend Right Period (September 15-29, 2025) will forfeit their right to the special dividend due to due bill procedures.
• The company has no obligation for the amount or processing of due bills, placing the burden on brokers and individual investors to understand the procedures.

Risks

• Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially and adversely from those expressed or implied.
• Other risks relating to the company's business are detailed in its latest Form 10-K and subsequent Forms 10-Q and/or Form 8-K filings with the SEC, especially under the heading 'Risk Factors'.

Future Outlook

Management is evaluating various strategic transactions and high-value strategic alternatives, expressing optimism about the company's future and plans to transform the company. A definitive proxy statement for the 2025 Annual Meeting, which will include proposals related to an Investment Transaction, is expected to be filed by the end of September 2025.

Management Comments

• "I'd like to assure my fellow stockholders that the payout of the special dividend will not affect our ability to pursue the various strategic transactions we are currently evaluating."
• "I look forward to obtaining stockholder approval for the annual meeting and various strategic proposals on the ballot in October and the ability to start executing on our exciting plans to transform the Company."
• "I continue to be extremely optimistic about our future as we explore several high-value strategic alternatives."

Industry Context

This announcement is specific to NovaBay's corporate actions regarding a special dividend and an upcoming annual meeting. It does not provide direct information on broader industry trends or competitive landscape, though the mention of 'strategic alternatives' could imply a response to market conditions or opportunities within the pharmaceutical sector.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Will receive a special cash dividend of $0.80 per share if they are stockholders of record on September 15, 2025, and do not sell their shares during the Dividend Right Period. Will vote on strategic proposals at the upcoming Annual Meeting.
• Brokers: Will be responsible for settling due bill obligations between buyers and sellers of common stock during the Dividend Right Period.
• Management/Employees: The company is pursuing strategic transactions and alternatives, which could impact the company's future direction and potentially employee roles or opportunities.

Next Steps

• Stockholders of record on September 15, 2025, will receive the special cash dividend on September 29, 2025.
• The company plans to file a definitive proxy statement with the SEC by the end of September 2025.
• The 2025 Annual Meeting of Stockholders will be held on October 16, 2025, to consider various strategic proposals, including those related to an Investment Transaction.
• Management will continue to pursue various strategic transactions and high-value strategic alternatives.

Key Dates

Recommendation

The special cash dividend of $0.80 per share is a positive return to shareholders, but the associated due bill procedures require careful attention for those trading around the record date. Management's optimistic outlook and pursuit of 'strategic alternatives' and an 'Investment Transaction' suggest potential future value creation, but the specifics of these initiatives are not yet disclosed. A 'hold' recommendation allows investors to benefit from the dividend while awaiting further details on the strategic direction and potential impact of the 'Investment Transaction' before making a more definitive investment decision.

Keywords

NovaBay Pharmaceuticals, NBY, Special Dividend, Cash Dividend, Due Bill, NYSE American, Annual Meeting, Proxy Statement, Stockholder Meeting, Corporate Governance, Strategic Alternatives, Pharmaceuticals